Related references
Note: Only part of the references are listed.Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis
Xi Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma
Patricia M. LoRusso et al.
PIGMENT CELL & MELANOMA RESEARCH (2020)
NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer
Timothy Nacarelli et al.
CANCER RESEARCH (2020)
Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review
Wouter Ouwerkerk et al.
MELANOMA RESEARCH (2019)
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan et al.
NATURE MEDICINE (2019)
N6-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance
Takeshi Fukumoto et al.
CANCER RESEARCH (2019)
HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
Takeshi Fukumoto et al.
CANCER RESEARCH (2019)
Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer
Young-Bae Kim et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC
Bonnie L. Bullock et al.
LIFE SCIENCE ALLIANCE (2019)
The epigenetic modifier PBRM1 restricts the basal activity of the innate immune system by repressing retinoic acid-inducible gene-I-like receptor signalling and is a potential prognostic biomarker for colon cancer
Xing-sheng Shu et al.
JOURNAL OF PATHOLOGY (2018)
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy
Ryuma Tokunaga et al.
CANCER TREATMENT REVIEWS (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
Jianfeng Shen et al.
NATURE MEDICINE (2018)
Targeted in situ genome-wide profiling with high efficiency for low cell numbers
Peter J. Skene et al.
NATURE PROTOCOLS (2018)
A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing
Deng Pan et al.
SCIENCE (2018)
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao et al.
SCIENCE (2018)
Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches
Giuseppe Palmieri et al.
CURRENT ONCOLOGY REPORTS (2018)
ARID2 modulates DNA damage response in human hepatocellular carcinoma cells
Atsushi Oba et al.
JOURNAL OF HEPATOLOGY (2017)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
Sara Gandini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Chromatin remodeling gene ARID2 targets cyclin D1 and cyclin E1 to suppress hepatoma cell progression
Yujie Duan et al.
ONCOTARGET (2016)
ARID2: A new tumor suppressor gene in hepatocellular carcinoma
Hong Zhao et al.
Oncotarget (2015)
Vulnerabilities of Mutant SWI/SNF Complexes in Cancer
Katherine C. Helming et al.
CANCER CELL (2014)
SWI/SNF Chromatin Remodeling Enzymes in Melanocyte Differentiation and Melanoma
A. Mehrotra et al.
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION (2014)
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence et al.
NATURE (2014)
Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma
Gilles Manceau et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Interferon-γ biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells
Ryousuke Satou et al.
FASEB JOURNAL (2012)
SWI/SNF nucleosome remodellers and cancer
Boris G. Wilson et al.
NATURE REVIEWS CANCER (2011)
PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes
ZJ Yan et al.
GENES & DEVELOPMENT (2005)
Share Paper
